Patents by Inventor Nigel Richard Whittle

Nigel Richard Whittle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6123948
    Abstract: Fusion polypeptides and aggregates of polypeptides comprising papillomavirus-derived antigens, and compositions thereof and their use e.g. with adjuvants for immunogenic and vaccine purposes in eliciting e.g. HPV-specific immune responses. The polypeptides can be purified to result in aggregates which when in solution or dispersion can pass through a sterilisation filter, and in amorphous aggregates. An example of such a polypeptide is a fusion protein of human papillomavirus proteins L2 and E7.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: September 26, 2000
    Assignee: Cantab Pharmaceuticals Research Limited
    Inventors: Nigel Richard Whittle, Jeremy Paddon Carmichael, Stephen Edward Connor, Henry Stephen Grammer Thompson, Mark Jonathan Wilson
  • Patent number: 5955087
    Abstract: Fusion polypeptides and aggregates of polypeptides comprising papillomavirus-derived antigens, and compositions thereof and their use e.g. with adjuvants for immunogenic and vaccine purposes in eliciting e.g. HPV-specific immune responses. The polypeptides can be purified to result in aggregates which when in solution or dispersion can pass through a sterilisation filter, and in amorphous aggregates. An example of such a polypeptide is a fusion protein of human papillomavirus proteins L2 and E7.
    Type: Grant
    Filed: February 23, 1996
    Date of Patent: September 21, 1999
    Assignee: Cantab Pharmaceuticals Research Limited
    Inventors: Nigel Richard Whittle, Jeremy Paddon Carmichael, Stephen Edward Connor, Henry Stephen Grammer Thompson, Mark Jonathan Wilson
  • Patent number: 5677425
    Abstract: The present invention provides an altered antibody molecule (AAM) having a hinge region which has a different number of cysteine residues from that found in the hinge region normally associated with the CH1 domain of the antibody molecule and a process for producing the same using recombinant DNA technology.
    Type: Grant
    Filed: August 18, 1994
    Date of Patent: October 14, 1997
    Assignee: Celltech Therapeutics Limited
    Inventors: Mark William Bodmer, John Robert Adair, Nigel Richard Whittle